'Armored' CAR T Cells Show Early Promise in Relapsed B-Cell ALL

(MedPage Today) — At the recent American Society of Hematology annual meeting, phase I data highlighted a next-generation, CD19-targeted, interleukin-18-secreting “armored” CAR T-cell therapy that is designed to enhance persistence and antileukemic…

Source link : https://www.medpagetoday.com/meetingcoverage/ashvideopearlsall/119164

Author :

Publish date : 2025-12-23 17:16:00

Copyright for syndicated content belongs to the linked Source.

M	T	W	T	F	S	S
						1
2	3	4	5	6	7	8
9	10	11	12	13	14	15
16	17	18	19	20	21	22
23	24	25	26	27	28

‘Armored’ CAR T Cells Show Early Promise in Relapsed B-Cell ALL

FDA Approves First Oral Medication for Iron Deficiency in Kids

Long-Term Tofersen Use May Slow ALS Progression, 3-Year Data Suggest

Related Posts

Exercise Cuts Cancer Mortality Risk in Less Common Types of Cancer, Too

Trump Team Taps New Acting CDC Director

Antibody-Oligonucleotide Conjugate Shows Promise in Myotonic Dystrophy Type 1

What Action Will RFK Jr. Take on Ultraprocessed Foods?

Q&A: ANA’s President on the Death of Nurse Alex Pretti and More

FDA Approves Monthly Dosing of Rybrevant Faspro for NSCLC

Exercise Cuts Cancer Mortality Risk in Less Common Types of Cancer, Too

Trump Team Taps New Acting CDC Director

Antibody-Oligonucleotide Conjugate Shows Promise in Myotonic Dystrophy Type 1

What Action Will RFK Jr. Take on Ultraprocessed Foods?

Q&A: ANA’s President on the Death of Nurse Alex Pretti and More

FDA Approves Monthly Dosing of Rybrevant Faspro for NSCLC

Novel Rapid-Acting Drug Proves Effective in Severe PTSD

Sugary Drinks and Anxiety; Psychedelics Succeed for Depression; Obsessional Jealousy

Categories

Archives